Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH

Nikos Emmanouilidis1, Jörg A Müller2, Mark D Jäger1, Stephan Kaaden1, Fabian A Helfritz1, Zeynep Güner1, Holger Kespohl1, Wolfgang Knitsch1, Wolfram H Knapp2, Jürgen Klempnauer1 and Georg F W Scheumann1

1Klinik für Viszeral- und Transplantationschirurgie and 2Klinik für Nuklearmedizin, Medizinische Hochschule Hannover, Carl-Neuberg Straße 1, Rudolf-Pichlmayr Transplantations-Forschungszentrum, OE 6220, D-30625 Hannover, Germany

(Correspondence should be addressed to N Emmanouilidis; Email: emmanouilidis.nikos@mh-hannover.de)

Abstract

Objective: The objective of this study was to determine whether the use of recombinant human TSH (rhTSH) to stimulate radioiodine uptake after thyroidectomy is as efficacious as a period of withholding thyroid hormones, while at the same time avoiding hypothyroidism, reducing sick leave time and shortening the hospital stay.

Design: Our aim was to compare the standard procedure of differentiated thyroid cancer treatment, which consists of thyroidectomy followed by 4 weeks of hypothyroidism and a conclusive ablative activity of 131iodine, with a new shortened treatment in which l-thyroxine (T4) medication is initiated a day after thyroidectomy, followed by application of rhTSH stimulation and subsequent ablation a few days after surgery. We presumed our treatment to represent the most sophisticated strategy for the reduction in sick leave days overall without any reduction in safety or the efficacy of ablative therapy.

Methods: Patients (n=25) were randomized either for surgery and rhTSH stimulation or surgery and l-T4 abstinence before the first application of radioiodine. Ablation success was determined by neck ultrasound and serum thyroglobulin during follow-up. RhTSH receivers were monitored for an average of 635 days (S.D. ± 289) and patients in l-T4 abstinence for an average of 624 days (S.D. ± 205). Both groups were statistically compared for significant differences in treatment efficacy, safety and overall time of sick leave.

Results and conclusions: Our shortened treatment proved to be equally efficacious and safe in comparison with the conventional therapy regimen. At the same time, it showed economic advantages through the reduction in average sick leave time from ~29 days (l-T4 abstinence) down to ~6 days (rhTSH stimulation) as well as sustaining the patient’s quality of life by the complete avoidance of hypothyroidism.

European Journal of Endocrinology 161 763–769

Introduction

The current standard treatment for differentiated thyroid cancer (DTC) of follicular or papillary histology consists of surgery – which entails the complete removal of the thyroid gland and, in our centre, a central cervical lymphadenectomy – followed by radioablatative therapy (RAT) to destroy any possibly remaining thyroid tissue or existing concurrent micro-metastatic satellites (1–3). In order to have a sufficient 131iodine uptake into any remnant thyroid tissue, an elevated TSH level of > 30 mU/l is mandatory. Before genetically engineered recombinant human TSH (rhTSH) was available, the only way to generate an elevated endogenous TSH was by thyroid hormone abstinence for a period of about 4 weeks after surgery. During this time, patients had to endure the debility and fatigue of a slowly developing hypothyroidism as well as socio-economic side effects (4–7). Since rhTSH has been introduced for clinical applications (8, 9) it has proven its value for thyroid cancer therapy in a number of studies (10, 11). In the clinical setting, rhTSH has been applied for two different purposes: primarily as a diagnostic tool on patients’ routine follow-up examinations (9, 12) and secondly in RAT settings (13–16).

That high serum levels of TSH can be achieved regularly by the application of rhTSH – even if l-thyroxine (T4) medication is maintained – and that stimulation with rhTSH is safe and effective has been repeatedly reported (8, 9, 12–17).

If l-T4 medication is maintained, and thus hypothyroidism is avoided, the patients’ quality of life can be
sustained and the number of sick leave days can be reduced, as well as avoiding potential morbidity associated with hypothyroidism (6, 9, 18). Various studies have related the reduction in sick leave days to the cost of rhTSH applications. While one study reported a somewhat unfavourable cost–benefit analysis (19), several others concluded that the use of rhTSH represents good value for money with benefits to patients and society (10). Recently, Borget et al. reported a reduction in sick leave time by 8.1 days and calculated the savings as high as €1083 per follow-up control in active patients (11).

While the costs per course of rhTSH application and RAT are more or less constant, it is comprehensible that the two decisive parameters for overall expenses are sick leave time and the costs in terms of loss of productivity per day. The cost/benefit ratio is enhanced by the reduction in the costs of loss of productivity and the shortened overall sick leave time. While the costs in loss of productivity are difficult to estimate and thus quite naturally lead to controversy, it is undisputed that savings due to the reduction in sick leave time at some point will offset the expenses for rhTSH. Up until the present day, there has been little focus on the initial phase of DTC treatment (the time period from surgery to the day of the first RAT) with regard to a possible reduction in hospitalization time and sick leave time.

At our clinic, it was common procedure for patients diagnosed with DTC to receive the first RAT as soon as possible after complete thyroidectomy. This meant that the patients remained l-T4 abstant from the first postoperative day onward until the endogenous TSH levels were high enough to receive the first course of RAT. This happened regularly within 4–6 weeks after surgery. Although in some cases – mostly in elderly patients with a slow pituitary response – the time point of RAT had to be further delayed by a few weeks.

In this study, we wanted to test our shortened Medizinische Hochschule Hannover (MHH) treatment, which combines surgery as well as the primary course of RAT within the first hospitalization period, thus emphasizing that a large proportion of reducible sick leave time lies within this first period. We estimated that for rhTSH receivers the overall sick leave time for surgery and RAT together may be reduced by around 75% when compared with patients preconditioned by l-T4 abstinence – without any reduction in safety or efficacy.

Subjects and methods

Study patients

Between January 2006 and June 2006, we recruited n = 25 subjects from a cohort of patients with a diagnosis of DTC or from patients that were thyroidectomized due to multinodular struma and who had a coincidental histology of DTC (Table 1). All of them were thyroidectomized and received a Klã/b central lymphadenectomy. The patients gave written informed consent to participate in the study, which was approved by the institutional review board and ethics committee. Thirteen patients were randomized to stimulation by rhTSH (female n = 10; male n = 3; mean age = 45.2 years; s.d. ± 16.5 years.) and twelve for preconditioning by l-T4 abstinence (female n = 8; male = 4; mean age = 54.8 years; s.d. ± 12.8 years). RhTSH participants received their first RAT on first hospitalization, while patients in l-T4 abstinence group were discharged from the surgery ward and, while in a state of distinctive hypothyroidism, were re-hospitalized for the first RAT within 4–6 weeks after thyroidectomy (Fig. 1).

Recombinant human TSH

rhTSH (Thyrogen, Genzyme, Cambridge, MA, USA) with a biological potency of 10 U/mg of protein was used according to the manufacturer’s instructions. Each vial containing 0.9 mg of rhTSH-alfa was dissolved in 1.2 ml of water for injection and administered by the i.m. route to the gluteal region 48 and 24 h before RAT.

Radioablative therapy

After iodine uptake was confirmed by neck scan with 100 MBq 131I, the ablative activity of 3700 MBq 131I was administered orally.

Laboratory measurements

Serum levels of T4, 3.5,3',-triiodothyronine, TSH, thyroglobuline (Tg), urinary iodine excretion and urinary creatinine were measured on examination days.

Scintigraphy

Whole body scans and scans of the neck region were conducted before RAT, at the time of RAT as well as 3 and 12 months after surgery. Additional scans were then performed on an annual basis and depending on the results of ultrasound (US) examinations and Tg readings (Table 2). Scans at follow-up were performed after l-T4 withdrawal using 100–600 MBq of 131Iodine.

Ablation in terms of radioactivity reception was considered to be successful if <2.0% of the applied activity was taken up in the thyroid bed and no extra-thyroidal uptake was noted. If a local DTC recurrence was suspected, e.g. due to elevated Tg levels or due to US examination, a patient would receive an ablative activity of 3700 MBq 131Iodine even if the diagnostic scintigraphy beforehand was negative for tumour recurrence. Thus, diagnostic scans in these cases were performed using higher activities than the standard 100–600 MBq.
Ultrasound

US of the neck region was carried out at the time of RAT, at 3- and 12-month intervals after surgery and subsequently at each follow-up examination. If the US revealed suspiciously enlarged lymph nodes or a suspicious paratracheal mass, an additional follow-up scintigraphy was planned and carried out shortly thereafter.

Statistical analysis

Statistical analysis was performed using Analyse-it for Microsoft Excel (version 2.00; Analyse-it Software, Ltd, Leeds, UK, http://www.analyse-it.com/; 2007). Distribution for normality was tested on descriptive statistics. A non-parametric U test (Mann–Whitney U test) was performed to check the significance of underlying hypothesis.

Results

A cohort of n=25 patients with DTC was surgically treated by total thyroidectomy and central cervical lymphadenectomy. Thirteen patients were randomized to stimulation by rhTSH and twelve for preconditioning by L-T4 abstinence. The age distribution in both groups was normal and there was no significant difference between rhTSH receivers and L-T4 abstinence.

In those receiving rhTSH, n=7 (54%) patients were in employment, n=3 (23%) were housewives and n=3 (23%) were pensioners. In the group of patients undergoing L-T4 abstinence (hypothyroidism), n=6 (46%) patients were employees, n=4 (31%) were housewives and n=2 (23%) patients were pensioners.

The mean tumour size for rhTSH receivers was 16.4 mm (s.d. ± 10.4 mm), with one measurement for tumour size missing. The mean tumour size in patients preconditioned by L-T4 abstinence was 8.9 mm.
The treatment efficacy of the two competing therapeutic strategies rhTSH substitution versus l-T4 abstinence was verified and compared by US, measurements of Tg levels and uptake of radioiodine in the neck region during follow-up (Table 2). The course of Tg decrease over time when graphically plotted was visually the same for rhTSH receivers and patients in l-T4 abstinence (results not shown). Tg levels directly before the initial RAT and on the last follow-up control day were compared: the mean value of Tg in rhTSH receivers was 8.02 ng/ml (s.d. ± 16.47; median = 2.20) directly before the first RAT and 0.10 g/l (s.d. ± 0.27; median = 0.00) on the last follow-up control day. The mean value of Tg in l-T4 abstinence was 8.29 g/l (s.d. ± 11.18; median = 4.11) directly before first RAT and 0.28 g/l (s.d. ± 0.65; median = 0.00) on the last follow-up control day. There was no statistically significant difference in Tg levels directly before the first RAT (two-tailed $P=0.2471$; Mann–Whitney $U$ test) and on the last follow-up control (two-tailed $P=0.1000$; Mann–Whitney $U$ test). The most recent Tg values were acquired at a mean post-operative time of 635 days (s.d. ± 289; median = 617 days) for rhTSH receivers and for patients in l-T4 abstinence at 624 days (s.d. ± 205; median = 665 days; two-tailed $P=0.8938$; Mann–Whitney $U$ test).

www.eje-online.org
## Table 2  Follow-up data of neck ultrasound (US), thyroglobulin reading (TG) and neck scan (Sc).

<table>
<thead>
<tr>
<th>Patient</th>
<th>rhTSH</th>
<th>L-T4 abstinence</th>
<th>RAT*</th>
<th>Follow-up I</th>
<th>Follow-up II</th>
<th>Follow-up III</th>
<th>Follow-up IV</th>
<th>Follow-up V</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Neg</td>
<td>0.8</td>
<td>1.1</td>
<td>116</td>
<td>Neg</td>
<td>0</td>
<td>3.5</td>
<td>350</td>
</tr>
<tr>
<td>2</td>
<td>Neg</td>
<td>1.5</td>
<td>2.7</td>
<td>100</td>
<td>Neg</td>
<td>0</td>
<td>1.6</td>
<td>399</td>
</tr>
<tr>
<td>3</td>
<td>TB, 2.7</td>
<td>23.5</td>
<td>4.3</td>
<td>102</td>
<td>Neg</td>
<td>0</td>
<td>0.5</td>
<td>365</td>
</tr>
<tr>
<td>4</td>
<td>Neg</td>
<td>0.9</td>
<td>2.5</td>
<td>113</td>
<td>Neg</td>
<td>0</td>
<td>0.3</td>
<td>375</td>
</tr>
<tr>
<td>5</td>
<td>TB, 0.1</td>
<td>0</td>
<td>0.3</td>
<td>116</td>
<td>Neg</td>
<td>0</td>
<td>0.2</td>
<td>364</td>
</tr>
<tr>
<td>6</td>
<td>Neg</td>
<td>2.9</td>
<td>1.2</td>
<td>119</td>
<td>Neg</td>
<td>0</td>
<td>1.1</td>
<td>366</td>
</tr>
<tr>
<td>7</td>
<td>TB, 0</td>
<td>2.3</td>
<td>96†</td>
<td>Neg†</td>
<td>0</td>
<td>0†</td>
<td>289</td>
<td>Neg</td>
</tr>
<tr>
<td>8</td>
<td>TB, 0</td>
<td>58.6</td>
<td>0.5</td>
<td>92</td>
<td>Neg</td>
<td>0</td>
<td>0</td>
<td>Discontinued follow-up due to unknown address</td>
</tr>
<tr>
<td>9</td>
<td>Neg</td>
<td>0</td>
<td>1.2</td>
<td>123</td>
<td>Neg</td>
<td>0</td>
<td>1.2</td>
<td>366</td>
</tr>
<tr>
<td>10</td>
<td>Neg</td>
<td>0</td>
<td>0.0</td>
<td>128†</td>
<td>Neg†</td>
<td>0</td>
<td>0†</td>
<td>231</td>
</tr>
<tr>
<td>11</td>
<td>Neg</td>
<td>3.1</td>
<td>2.9</td>
<td>131</td>
<td>Neg</td>
<td>0</td>
<td>0.8</td>
<td>369</td>
</tr>
<tr>
<td>12</td>
<td>Neg</td>
<td>1</td>
<td>0.4</td>
<td>125†</td>
<td>TB, 1.45†</td>
<td>1.7†</td>
<td>156</td>
<td>Neg</td>
</tr>
<tr>
<td>13</td>
<td>TB, 0</td>
<td>23.6</td>
<td>2.7</td>
<td>102</td>
<td>Neg</td>
<td>0</td>
<td>0.8</td>
<td>396</td>
</tr>
<tr>
<td>14</td>
<td>Neg</td>
<td>10.5</td>
<td>2.0</td>
<td>109</td>
<td>Neg</td>
<td>1.1</td>
<td>1.7</td>
<td>214</td>
</tr>
<tr>
<td>15</td>
<td>Neg</td>
<td>0.3</td>
<td>2.3</td>
<td>127</td>
<td>Neg</td>
<td>0</td>
<td>0.3</td>
<td>357</td>
</tr>
<tr>
<td>16</td>
<td>Neg</td>
<td>6.4</td>
<td>1.9</td>
<td>92</td>
<td>Neg</td>
<td>0</td>
<td>1.2</td>
<td>405</td>
</tr>
<tr>
<td>17</td>
<td>TB, 1.6</td>
<td>12.3</td>
<td>9.1</td>
<td>112†</td>
<td>LN, 0.7†</td>
<td>3.3†</td>
<td>232</td>
<td>Neg</td>
</tr>
<tr>
<td>18</td>
<td>Neg</td>
<td>4.4</td>
<td>9.1</td>
<td>113</td>
<td>Neg</td>
<td>0</td>
<td>2.1</td>
<td>250</td>
</tr>
<tr>
<td>19</td>
<td>TB, 1.9</td>
<td>1.9</td>
<td>4.1</td>
<td>113†</td>
<td>TB, 0.3</td>
<td>1.4</td>
<td>115</td>
<td>Neg</td>
</tr>
<tr>
<td>20</td>
<td>Neg</td>
<td>0</td>
<td>1.7</td>
<td>127</td>
<td>Neg</td>
<td>0</td>
<td>1.0</td>
<td>263</td>
</tr>
<tr>
<td>21</td>
<td>Neg</td>
<td>3.7</td>
<td>1.9</td>
<td>97</td>
<td>Neg</td>
<td>2.9</td>
<td>0.8</td>
<td>302</td>
</tr>
<tr>
<td>22</td>
<td>TB, 0.3</td>
<td>3.8</td>
<td>2.2</td>
<td>124†</td>
<td>TB, 0.3</td>
<td>1.9</td>
<td>263</td>
<td>Neg</td>
</tr>
<tr>
<td>23</td>
<td>TB, 0.3</td>
<td>23.7</td>
<td>6.0</td>
<td>117†</td>
<td>Neg†</td>
<td>0</td>
<td>1.2†</td>
<td>231</td>
</tr>
<tr>
<td>24</td>
<td>Neg</td>
<td>1.5</td>
<td>2.1</td>
<td>118</td>
<td>Neg</td>
<td>0</td>
<td>0.8</td>
<td>368</td>
</tr>
</tbody>
</table>

TB, thyroid bed; LN, lymph node; F, follow-up in progress.
*First RAT.
†First additional RAT.
‡Second additional RAT.
§Re-operation.
Follow-up scintigraphies after surgery and first RAT were routinely carried out using body mass index-adjusted activities of $^{131}$Iodine at 400–600 MBq. If tumour recurrence was suspected – due to sonographic imaging or elevated Tg values – an additional diagnostic scintigraphy was conducted. If the diagnostic scan revealed a suspicious radioactivity reception in the neck region and if tumour recurrence was suspected, then the diagnostic scans were followed up by an additional ablative activity of 3700 MBq $^{131}$Iodine. Additional RAT due to suspected tumour recurrence was conducted for three patients in rhTSH receivers and for four patients in $\alpha$-T4 abstinence (Table 2). US by itself did not lead to additional RAT, whereas for two patients in rhTSH receivers and one patient in $\alpha$-T4 abstinence a positive diagnostic scan lead to suspicion for tumour recurrence and thus were followed up by an additional ablative activity of 3700 MBq $^{131}$Iodine, despite a negative US examination (Table 2). One patient from the group of rhTSH receivers had to be re-operated 2 1/2 years after initial therapy due to a supra-clavicular lymph node metastasis. Overall, follow-up scans showed visually comparable results over a period of time at uptake percentages usually below 2% of administered activity in the neck region (results not shown).

**Discussion**

Since its introduction for clinical applications, rhTSH has proven its value in the management of thyroid cancer, both in clinical studies and from a pharmacoeconomic perspective. In clinical settings, rhTSH has been used for two main indications: first, for diagnostic purposes in routine follow-up, and secondly, in the ablation of remnant thyroid tissue after (near) total thyroidectomy.

We used rhTSH as a tool to substitute endogenous TSH at high-serum levels and was able to combine surgery and RAT in quick succession during the first hospitalization. This significantly shortened the overall treatment time of first-line therapy (thyroidectomy and RAT) down to 10 days, which equals a time reduction in first-line therapy of about 75% when compared with the conventional approach of preconditioning by $\alpha$-T4 abstinence after thyroidectomy. Additionally and despite the relatively small number of patients, we also found a significant reduction in sick leave time from ~29 days down to ~6 days if the patients were preconditioned by rhTSH rather than by withdrawal of $\alpha$-T4 medication. At the same time, we found our MHH procedure to be safe and equally effective when compared with the standard procedure of $\alpha$-T4 abstinence. Furthermore, hypothyroidism was avoided completely in patients preconditioned by rhTSH. In addition, those patients made only one trip to the hospital and received their complete therapy in one package. Thus, patients preconditioned by rhTSH were able to deal with the diagnosis of cancer quicker and their perception of ‘illness’ might not have been so negative.

Although we have presented preliminary results of a still ongoing study, it seems comprehensible why at our institution today we strongly favour the utilization of rhTSH to combine surgery and first RAT within the first hospitalization. An additional study with more patients and a focus on the pharma-economic impact of this shortened protocol are in progress.

**Declaration of interest**

All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This research did not receive any specific grant from any funding agency in the public, commercial, or non-profit sector.

**Acknowledgements**

Oliviera Dragicevic.

**References**


13 Kohlfuerst S, Igerc I & Lind P. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid 2005 15 371–376.


Received 10 August 2009
Accepted 14 August 2009